Compare Citius Pharmaceuticals Inc (CTXR) vs HubSpot Inc (HUBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs HubSpot Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while HubSpot Inc trades at $229.08 (market cap $11.56B). The key difference: HubSpot Inc is far larger — about 848.8× Citius Pharmaceuticals Inc's market cap, and HubSpot Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | HUBS | |
|---|---|---|
Market Cap | $13.62M | $11.56B |
Volume | 132,438 | 1,891,287 |
Sector | Health | Technology |
52-Week High | $1.82 | $494.58 |
52-Week Low | $0.48 | $170.39 |
Enterprise Value | $3.79M | $10.46B |
Typical Hold Time | — | 78 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
HubSpot (HUBS) trades at $228.96, up 3.93% with strong technical momentum and bullish moving averages. The company shows accelerating revenue growth, reaching $3.13B in 2025 with net income turning positive at $45.91M. Recent analyst day highlighted AI strategy enhancements and margin expansion targets, while institutional buying and positive earnings beats support investor confidence. Technical indicators show the stock trading near pivot point resistance at $228 with RSI suggesting potential overbought conditions.
Outlook remains positive with 57% analyst buy ratings and $243.65 consensus target, though high P/E of 82.5x demands sustained growth execution. Key risks include AI competition pressure and valuation sensitivity to earnings momentum. The transition to profitability and strong cash flow generation provide fundamental support for continued upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
